Research Areas

We study how senescent cells persist by escaping immune surveillance. Our research connects cancer biology, aging and obesity with therapeutic strategies and biomarkers designed to guide the development of senescence-targeted interventions.

We study why senescent cells accumulate with age and how immune checkpoint pathways may protect them from clearance. Building on findings in aged mice, we investigate whether targeting PD-L2 can reduce senescent-cell burden and improve age-related health.

We investigate how senescent cancer cells evade immune clearance after chemotherapy. We identified PD-L2 as a checkpoint that supports an immunosuppressive tumor environment and limits CD8+ T-cell-mediated tumor regression. We aim to define these mechanisms and identify therapeutic targets to overcome treatment resistance and prevent recurrence that may improve responses to cancer treatment.

We investigate how senescent cells contribute to metabolic and physical dysfunction during aging and obesity. Our work connects senescence biology with immune regulation to identify therapeutic targets shared across these conditions.

We investigate biomarkers that could help assess senescent-cell burden and support the development of therapies that target senescence. We identified soluble PD-L2 as a candidate biomarker. This work connects mechanistic studies with translational research to improve how senescence is measured in cancer and age-related disease.